FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to laboratory diagnostics and oncology, and concerns detection of tumour presence in patient in vitro. To this end, obtaining a biological sample obtained from said patient, extracting the extracellular vesicles from the above sample, wherein the step for extracting extracellular vesicles involves isolating TM9SF4-positive extracellular vesicles, in/on extracellular TM9SF4-positive vesicles recovered at stage b), the level or presence of the CD9, miR-21 or RNU6 biomarker is determined and the level or availability of the biomarker determined at step c) is compared to one or more reference values. Also disclosed is a method of determining a tumour transformation state in a patient in vitro, a tumour detection kit and a set for determining the tumour transformation state.
EFFECT: group of inventions enables detecting a tumour, as well as determining the tumour transformation state in a patient in vitro.
19 cl, 16 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
| NEW TUMOUR BIOMARKER | 2010 |
|
RU2714750C2 |
| DELIVERY OF THERAPEUTIC POLYPEPTIDES VIA PSEUDOTYPED ONCOLYTIC VIRUSES | 2017 |
|
RU2758007C2 |
| CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| CHIMERIC PROTEINS BASED ON TIGIT AND LIGHT | 2018 |
|
RU2775490C2 |
| COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS | 2016 |
|
RU2766200C1 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2770002C2 |
| ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
